Study Summary
The purpose of this study is to test the safety and efficacy of GD2-CART01, a CAR T cell treatment targeting GD2 in paediatric or young adult patients with High Risk and/or relapsed/refractory Neuroblastoma. A small exploratory cohort of patients with GD2-positive tumors other than Neuroblastoma has also been included.
Want to learn more about this trial?
Request More InfoInterventions
GD2-CART01BIOLOGICAL
Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 10.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Ospedale Pediatrico Bambino Gesù | Roma | Italy |